Squamous Cell Carcinoma - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
153 Pages - GMD12034
$2,000.00

Summary

Global Markets Direct’s, ‘Squamous Cell Carcinoma - Pipeline Review, H1 2014’, provides an overview of the Squamous Cell Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Squamous Cell Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Squamous Cell Carcinoma Overview 9
Therapeutics Development 10
Pipeline Products for Squamous Cell Carcinoma - Overview 10
Pipeline Products for Squamous Cell Carcinoma - Comparative Analysis 11
Squamous Cell Carcinoma - Therapeutics under Development by Companies 12
Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 15
Squamous Cell Carcinoma - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Squamous Cell Carcinoma - Products under Development by Companies 20
Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes 22
Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 23
Boehringer Ingelheim GmbH 23
Novartis AG 24
Genmab A/S 25
Celgene Corporation 26
Clinuvel Pharmaceuticals Limited 27
Oncolytics Biotech Inc. 28
Oryzon Genomics S.A. 29
Hutchison MediPharma Limited 30
Merrimack Pharmaceuticals, Inc. 31
Neotropix, Inc. 32
Axelar AB 33
Onconova Therapeutics, Inc. 34
Omeros Corporation 35
Cellceutix Corporation 36
Cannabis Science, Inc. 37
Oncovir, Inc. 38
Genextra S.p.a. 39
Bexion Pharmaceuticals, LLC. 40
AbbVie Inc. 41
Squamous Cell Carcinoma - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Target 44
Assessment by Mechanism of Action 47
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
afatinib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
paclitaxel albumin-bound - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AXL-1717 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
pelareorep - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
rigosertib sodium - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
afamelanotide - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
boanmycin hydrochloride + [docetaxel] - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
CIGB-128 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DAC-0060 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Poly-ICLC - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
BYL-719 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
LJM-716 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
interleukin-15 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Antibody Drug Conjugate for Squamous Cell Tumor - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
irinotecan sucrosofate liposomal - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Kevetrin - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
CUV-9900 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
BXQ-350 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
CS-TATI-1 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
CS-S/BCC-1 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
TF-011-Monomethyl Auristatin E - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
AMXT-1501 + eflornithine - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Allogenic Mesenchymal Stem Cells - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
HMPL-453 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
NTX-500 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
GPR87 Antagonist for Cancer - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Monoclonal Antibody For Squamous Cell Cancer - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Drugs for Cutaneous Squamous Cell Carcinoma (cSCC) - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Squamous Cell Carcinoma - Recent Pipeline Updates 105
Squamous Cell Carcinoma - Dormant Projects 142
Squamous Cell Carcinoma - Discontinued Products 143
Squamous Cell Carcinoma - Product Development Milestones 144
Featured News & Press Releases 144
Nov 05, 2013: ImmunoGen Initiates Phase I Testing of Its EGFR-Targeting ADC, IMGN289 144
Jul 02, 2013: VentiRx Pharmaceuticals Initiates the ACTIVE8 Phase 2 Clinical Trial Evaluating VTX-2337 in Combination with Cetuximab and Chemotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 144
Jun 06, 2013: Taiho Pharma Presents Results Of Phase III Trials Of TS-1 On Patients With Colorectal Cancer And Head And Neck Cancers At ASCO 145
May 15, 2013: Synta Pharma Announces Presentations On Ganetespib Clinical Trials At 2013 ASCO Annual Meeting 146
Mar 28, 2013: Oncolytics Biotech Meets Primary Overall Statistical Endpoint In US Phase II Study Of Reolysin In Squamous Cell Lung Cancer 147
Feb 08, 2013: Oncolytics Biotech Announces Additional Positive Reolysin Clinical Trial Data From Phase II Study In Squamous Cell Carcinoma Of Lung 148
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma 148
Sep 06, 2012: NCCN Oncology Research Program Receives Funding From GSK To Evaluate Clinical Effectiveness Of Trametinib 149
Jul 06, 2012: Navidea To Present Data From Lymphoseek Program At Upcoming Upcoming Scientific Meetings In July 150
Apr 04, 2012: Berg Pharma Presents Data On BPM 31510 At AACR Meeting 2012 151
Appendix 152
Methodology 152
Coverage 152
Secondary Research 152
Primary Research 152
Expert Panel Validation 152
Contact Us 153
Disclaimer 153

List of Tables
Number of Products under Development for Squamous Cell Carcinoma, H1 2014 10
Number of Products under Development for Squamous Cell Carcinoma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Development by Companies, H1 2014 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2014 22
Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2014 23
Squamous Cell Carcinoma - Pipeline by Novartis AG, H1 2014 24
Squamous Cell Carcinoma - Pipeline by Genmab A/S, H1 2014 25
Squamous Cell Carcinoma - Pipeline by Celgene Corporation, H1 2014 26
Squamous Cell Carcinoma - Pipeline by Clinuvel Pharmaceuticals Limited, H1 2014 27
Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H1 2014 28
Squamous Cell Carcinoma - Pipeline by Oryzon Genomics S.A., H1 2014 29
Squamous Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H1 2014 30
Squamous Cell Carcinoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 31
Squamous Cell Carcinoma - Pipeline by Neotropix, Inc., H1 2014 32
Squamous Cell Carcinoma - Pipeline by Axelar AB, H1 2014 33
Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H1 2014 34
Squamous Cell Carcinoma - Pipeline by Omeros Corporation, H1 2014 35
Squamous Cell Carcinoma - Pipeline by Cellceutix Corporation, H1 2014 36
Squamous Cell Carcinoma - Pipeline by Cannabis Science, Inc., H1 2014 37
Squamous Cell Carcinoma - Pipeline by Oncovir, Inc., H1 2014 38
Squamous Cell Carcinoma - Pipeline by Genextra S.p.a., H1 2014 39
Squamous Cell Carcinoma - Pipeline by Bexion Pharmaceuticals, LLC., H1 2014 40
Squamous Cell Carcinoma - Pipeline by AbbVie Inc., H1 2014 41
Assessment by Monotherapy Products, H1 2014 42
Assessment by Combination Products, H1 2014 43
Number of Products by Stage and Target, H1 2014 46
Number of Products by Stage and Mechanism of Action, H1 2014 49
Number of Products by Stage and Route of Administration, H1 2014 51
Number of Products by Stage and Molecule Type, H1 2014 53
Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2014 105
Squamous Cell Carcinoma - Dormant Projects, H1 2014 142
Squamous Cell Carcinoma - Discontinued Products, H1 2014 143

List of Figures
Number of Products under Development for Squamous Cell Carcinoma, H1 2014 10
Number of Products under Development for Squamous Cell Carcinoma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 42
Assessment by Combination Products, H1 2014 43
Number of Products by Top 10 Target, H1 2014 44
Number of Products by Stage and Top 10 Target, H1 2014 45
Number of Products by Top 10 Mechanism of Action, H1 2014 47
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 48
Number of Products by Top 10 Route of Administration, H1 2014 50
Number of Products by Stage and Top 10 Route of Administration, H1 2014 51
Number of Products by Top 10 Molecule Type, H1 2014 52
Number of Products by Stage and Top 10 Molecule Type, H1 2014 53

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax